Omega PF™ Device Achieves Major Milestone with First Human Implant at Dell Medical Center of University of Texas at Austin

 // News

October 18  

Aplos Medical, pioneers in the field of Gastroesophageal Reflux Disease (GERD) treatment, proudly announces the successful implantation of its revolutionary Omega PF™ device. The groundbreaking procedure took place in August 2023 at Dell Medical Center of University of Texas at Austin, performed by Dr. Tripp Buckley, a globally recognized expert in GERD surgical treatments.

“While Nissen fundoplication offers favorable surgical outcomes in experienced hands, the Omega device stands out for its promise of a simpler and swifter procedure, significantly reducing potential complications and side-effects,” Dr. Buckley said.

Surgeons have been treating GERD, or acid reflux, for more than 80 years. Traditional surgical treatments have their limitations, primarily addressing only reflux while causing bothersome side effects. Although esophageal restriction proves effective in stopping reflux, it unfortunately leads to dysphagia, as it equally restricts swallowing.

The Omega PF™ device heralds a paradigm shift in GERD treatment. Being the first of its kind, the device masterfully combines dual-modality treatment; it not only controls reflux but ensures a natural, uncompromised swallowing process for the patient. This innovative laparoscopic implant procedure can be easily replicated by all qualified surgeons. Once verified in clinical studies, the Omega PF™ will both represent a groundbreaking GERD treatment to benefit patients, surgeons, and payers – while setting a new standard of care in this field and representing the turning point of GERD treatments.

“We are delighted by this monumental achievement, performed by Dr. Buckley and his team,” Aplos Medical President and CEO Dr. Claude Tihon said. “The simple Omega PF™ device is designed to mitigate common issues seen with current GERD treatments. We look forward to further progress being made toward our ultimate goal of benefitting millions of individuals suffering from acid reflux.”

To learn more about the first-in-man Omega PF™ device implant – click here.

The clinical feasibility study is supported by our third National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)/National Institute of Health (NIH) SBIR grant.

About Aplos Medical

Aplos Medical offers innovative medical device solutions that help healthcare professionals perform at a higher level and enhance patient experience. The company’s Omega PF™ device will revolutionize treatment of Gastroesophageal Reflux Disease or GERD.

Success message!
Warning message!
Error message!